Recent chronic lymphocytic leukemia Articles
Learn about new financial assistance and COVID resources for those living with CLL (chronic lymphocytic leukemia) and those caring for someone who is.
There is good news in the advancement of chemo-free approaches to managing chronic lymphocytic leukemia, and I am thrilled to share it with you. Results of the phase III ECOG trial found that the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) came out superior to the chemotherapy and immunotherapy (chemoimmunotherapy) grouping of fludarabine, cyclophosphamide, and rituximab, known as FCR.
We are hearing a lot about cancer immunotherapy these days. Modern approaches and technology are now helping to revolutionize cancer care. What decision-making power do we hold to influence an immune-therapeutic response to help avoid, manage, or treat a cancer diagnosis? And how might this affect long-term survival?